LUXTURNA, Continues

LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight

07.08.2025 - 18:06:48 | prnewswire.co.uk

DelveInsight Business Research, LLP United States of America United Kingdom

 
+14699457679

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/luxturna-continues-to-lead-in-retinal-gene-therapy-with-increased-market-penetration--delveinsight-302407755.html

en | boerse | 67952577 |